Goldman initiated coverage on Arrowhead with a new price target
$ARWR
Biotechnology: Pharmaceutical Preparations
Health Care
Goldman initiated coverage of Arrowhead with a rating of Neutral and set a new price target of $31.00
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/5/2024 | $31.00 | Neutral | Goldman |
| 12/4/2023 | $29.00 | Buy | BofA Securities |
| 9/19/2023 | $33.00 | Neutral | Citigroup |
| 7/21/2023 | Outperform | TD Cowen | |
| 5/12/2023 | $40.00 | Outperform → Market Perform | SVB Securities |
| 4/26/2023 | $80.00 | Outperform | SMBC Nikko |
| 4/12/2023 | $21.00 → $35.00 | Market Perform → Outperform | SVB Securities |
| 3/21/2023 | $27.00 | Mkt Perform | Bernstein |
SCHEDULE 13G - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)
8-K - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Filer)
10-Q - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Filer)
- Milestone earned upon reaching first enrollment target in a Phase 1/2 study of ARO-DM1 for the treatment of type 1 myotonic dystrophy Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it has earned a $100 million milestone payment from Sarepta Therapeutics (NASDAQ:SRPT). The milestone was triggered when Arrowhead reached the first of two prespecified enrollment targets and subsequent authorization to dose escalate in a Phase 1/2 clinical study of ARO-DM1, an investigational RNA interference (RNAi) therapeutic for the treatment of type 1 myotonic dystrophy (DM1), the most common adult-onset muscular dystrophy. Arrowhead currently expects to achieve the second enrollment
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that as an inducement to entering into employment with the Company, on July 22, 2025, the Company's Board of Directors approved "inducement" grants to 38 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 52,680 restricted stock units. The grants are outside the Company's stockholder-approved equity incentive plans and vest annually over four years. About Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today issued a statement to address questions about the status of its ongoing Exclusive License and Collaboration Agreement with Sarepta Therapeutics. Arrowhead continues to conduct clinical and non-clinical studies as stipulated in the agreement, and it expects Sarepta to continue to meet its required financial obligations. Sarepta has provided no indication of any intention to fail to fulfill any of its obligations, however if that occurs there are clear termination provisions that would cause assets and associated intellectual property to be returned to Arrowhead. Arrowhead believes its strong balance sheet and multiple opportunities for addi
4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)
4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)
4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)
4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that, effective May 13, 2025, Arrowhead's Chief Financial Officer, Ken Myszkowski, will retire after 16 years of service to the company and will be succeeded by Daniel Apel, who has been appointed as the company's new Chief Financial Officer. Mr. Myszkowski will continue to serve as an employee adviser to assist and facilitate an effective transition. "Ken has been a valuable member of the Arrowhead team, and he retires at a time of great financial strength for the company. The finance organization that Ken built over the years is very capable and provides strong support to our ambitious development and commercialization plans.
NEW YORK, Jan. 22, 2025 /PRNewswire/ -- Guidewire Software Inc. (NYSE:GWRE) will replace Arrowhead Pharmaceuticals Inc. (NASD: ARWR) in the S&P MidCap 400, and Arrowhead Pharmaceuticals will replace Barnes Group Inc. (NYSE:B) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, January 27. S&P 500 constituent Apollo Global Management Inc. (NYSE:APO) is acquiring Barnes Group in a deal expected to be completed soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector January 27, 2025 S&P MidCap 400 Addition Guidewi
SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company's Board of Directors. The Company also announced that Patrick Machado has stepped down as a member of its Board of Directors. These changes became effective as of April 15, 2024. "I am pleased to welcome Will to our Board of Directors at this exciting time for Turnstone," said Sammy Farah, M.B.A.,
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it will host a webcast and conference call on August 7, 2025, at 4:30 p.m. ET to discuss its financial results for the fiscal 2025 third quarter ended June 30, 2025. Webcast and Conference Call and Details Investors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approximately two hours after the conclusion of the call. For analysts that wish to participate in the conference call, please register at https://register-conf.media-server.com/register/BI3955ca6732974874b0bc0ac323811a7f. Once registered, you w
- Conference Call and Webcast Today, May 12, 2025, at 4:30 p.m. ET Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced financial results for its fiscal 2025 second quarter ended March 31, 2025. The Company is hosting a conference call today, May 12, 2025, at 4:30 p.m. ET to discuss the results. "Arrowhead is in a strong and stable position as a business, and we have made meaningful progress towards our long-term goal of developing and ultimately commercializing new innovative medicines for millions of patients. We are on schedule to launch plozasiran this year, pending regulatory approval, with what we think is a best-in-class profile with meaningful differentiation from current
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it will host a webcast and conference call on May 12, 2025, at 4:30 p.m. ET to discuss its financial results for the fiscal 2025 second quarter ended March 31, 2025. Webcast and Conference Call and Details Investors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approximately two hours after the conclusion of the call. For analysts that wish to participate in the conference call, please register at https://register-conf.media-server.com/register/BI06c63c27dc8a4e368d2a8316c4143218. Once registered, you will
SC 13G - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)
SC 13G/A - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)
SC 13G/A - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)
Goldman initiated coverage of Arrowhead with a rating of Neutral and set a new price target of $31.00
BofA Securities initiated coverage of Arrowhead with a rating of Buy and set a new price target of $29.00
Citigroup initiated coverage of Arrowhead with a rating of Neutral and set a new price target of $33.00